According to new research, OTOF gene therapy has been shown to reverse hearing loss. The procedure involved injecting the OTOF gene into the inner ear, improving the hearing function of 10 participants. This is an Earth-shattering milestone in treating genetic deafness. Ultimately, researchers restored hearing in children and adults born with congenital deafness using just a single injection of a new gene therapy.
The study, led by Karolinska Institute in Sweden and published in Nature Medicine, treated ten patients with a genetic mutation in the OTOF gene, critical for auditory signal transmission. The small-scale trial included people who had a genetic form of deafness.
The therapy used a modified virus to deliver a healthy gene copy directly to the inner ear. Within just one month, all participants showed significant hearing improvements, with a seven-year-old regaining near-full hearing and engaging in normal conversations. The researcher noticed the average volume of perceptible sound improving from 106 decibels to 52 within the next six months.
Researcher Dr. Duan states, “OTOF is just the beginning. We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment”
This pioneering treatment marks the first time gene therapy has successfully reversed hearing loss in both children and adults. Not only was the treatment well-tolerated with no serious side effects, but it also opened the door to broader applications. Scientists now aim to target other, more common deafness-related genes such as GJB2 and TMC1. If successful, these future therapies could offer new hope to millions living with hearing impairments worldwide.
